Cempra Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Baird Remains Bullish Following Cempra's (CEMP) 4Q; Focus Remains on Solithromycin Launch
February 25, 2016 7:09 AM ESTBaird maintained an Outperform rating on Cempra, Inc. (NASDAQ: CEMP), and cut the price target to $33.00 (from $38.00), following the company's 4Q. Cempra is currently focused on completing regulatory submissions for Solithromycin in CABP and prepping for launch in 2017. As such, the company's 4Q results are... More
Cempra (CEMP) Tops Q4 EPS by 11c
February 24, 2016 4:26 PM ESTCempra (NASDAQ: CEMP) reported Q4 EPS of ($0.48), $0.11 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $5.79 million versus the consensus estimate of $3.89 million.
For earnings history and earnings-related data on Cempra (CEMP) click here.
... More